• 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

GENIL Share Price Performance

₺169.00
56.70 (50.49%)
₺169.00
56.70 (50.49%)
Price ₺169.00

GENIL Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with acceptable track record.

0 Risks
0 Rewards

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Key Details

₺14.6b

Revenue

₺11.7b

Cost of Revenue

₺2.9b

Gross Profit

₺2.3b

Other Expenses

₺672.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
2.24
20.09%
4.60%
23.9%
View Full Analysis

About GENIL

Founded
1997
Employees
672
CEO
Abidin Gulmus
WebsiteView website
www.genilac.com.tr

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.

Recent GENIL News & Updates

Recent updates

No updates

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Competitors